Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice

mAbs

Volumn 4, Issue 6, 2012, Pages 740-752

  Filipe, Vasco ^a,b   Jiskoot, Wim ^a   Basmeleh, Abdul Hafid ^b   Halim, Andhyk ^b   Schellekens, Huub ^b   Brinks, Vera ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Accelerated stress conditions; IgG; Immunogenicity; Protein aggregates; Transgenic mice

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; NANOPARTICLE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; FLUORESCENCE; FREEZE THAWING; GEL PERMEATION CHROMATOGRAPHY; HEATING; IMMUNOGENICITY; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN LIGHT CHAIN GENE; IMMUNOGLOBULIN STRUCTURE; IMMUNOLOGICAL TOLERANCE; MALE; MORPHOLOGY; MOUSE; NANOPARTICLE TRACKING ANALYSIS; NANOTECHNOLOGY; NONHUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; STAINING; TRANSGENICS;

ACCELERATED STRESS CONDITIONS; IGG; IMMUNOGENICITY; PROTEIN AGGREGATES; TRANSGENIC MICE;

ANIMALS; ANTIBODY FORMATION; EPITOPES; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; MICE, TRANSGENIC; PHARMACEUTICAL PREPARATIONS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION;

EID: 84869838281     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22066     Document Type: Article

References (53)

1. Lawrence S. Pipelines turn to biotech. Nat Biotechnol 2007; 25:1342; PMID:18066015; http://dx.doi.org/10.1038/nbt1207-1342
2. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460-8; PMID:21486979; http://dx.doi.org/10.1001/jama. 2011.406
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:921-6; PMID:17301106; http://dx.doi.org/10.1136/ard.2006. 065615
4. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457-62; PMID:12119747; http://dx.doi.org/10.1038/nrd818
5. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8:E501-7; PMID:17025268; http://dx.doi.org/10.1208/aapsj080359
6. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 1997; 14:1472-8; PMID:9358564; http://dx.doi.org/10.1023/A:1012193326789
7. Gamble CN. The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int Arch Allergy Appl Immunol 1966; 30:446-55; PMID:4163860; http://dx.doi.org/10.1159/000229829
8. Cheng PC, Steele CR, Gu L, Song W, Pierce SK. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. J Immunol 1999; 162:7171-80; PMID:10358163
9. Daha MR, van ES LA, Hazevoet HM, Kijlstra A. Degradation of soluble immunoglobulin aggregates in vitro by monocytes from normal subjects and from patients with systemic lupus erythematosus. Scand J Immunol 1982; 16:117-22; PMID:7134889; http://dx.doi.org/10.1111/j.1365-3083.1982.tb00705.x
10. Johnson R, Jiskoot W. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations. J Pharm Sci 2012; 101:3586-92; PMID:22736238; http://dx.doi.org/10.1002/jps.23248
11. Filipe V, Hawe A, Schellekens H, Jiskoot W. Aggregation and immunogenicity of therapeutic proteins. In: Wang W, Roberts CJ, eds. Aggregation of therapeutic proteins. New Jersey: John Wiley & Sons, 2010:403-33
12. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 2009; 98:2909-34; PMID:18823031; http://dx.doi.org/10.1002/jps.21566
13. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, et al. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 2011; 28:920-33; PMID:20972611; http://dx.doi.org/10.1007/s11095-010-0297-1
14. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 2009; 98:1201-5; PMID:18704929; http://dx.doi.org/10.1002/jps.21530
15. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci 2010; 99:3302-21; PMID:20310025; http://dx.doi.org/10.1002/jps.22097
16. Hawe A, Hulse WL, Jiskoot W, Forbes RT. Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates. Pharm Res 2011; 28:2302-10; PMID:21560019; http://dx.doi.org/10.1007/s11095-011-0460-3
17. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 2010; 27:796-810; PMID:20204471; http://dx.doi.org/10. 1007/s11095-010-0073-2
18. Barnard JG, Singh S, Randolph TW, Carpenter JF. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 2011; 100:492-503; PMID:20803602; http://dx.doi.org/10.1002/jps.22305
19. Wuchner K, Büchler J, Spycher R, Dalmonte P, Volkin DB. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. J Pharm Sci 2010; 99:3343-61; PMID:20229596; http://dx.doi.org/10.1002/jps.22123
20. Barnard JG, Rhyner MN, Carpenter JF. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions. J Pharm Sci 2012; 101:140-53; PMID:22109687; http://dx.doi.org/10. 1002/jps.22732
21. De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008; 8:620-6; PMID:18775515; http://dx.doi.org/10.1016/j.coph.2008.08.002
22. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 2010; 137:5-14; PMID:20708973; http://dx.doi.org/10.1016/j.clim.2010.06.018
23. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, et al. Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses. J Biol Chem 2012; 287:25266-79; PMID:22584577; http://dx.doi.org/10.1074/jbc.M111.330902
24. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 2006; 95:1084-96; PMID:16552750; http://dx.doi.org/10.1002/jps.20599
25. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 2010; 27:1812-24; PMID:20499141; http://dx.doi.org/10.1007/s11095-010-0172-0
26. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res 2011; 28:2379-85; PMID:21744171; http://dx.doi.org/10.1007/s11095-011-0523-5
27. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008; 14:191-202; PMID:18606364; http://dx.doi.org/10.1016/S1387-2656(08)00007-0
28. van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, et al. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods 2010; 352:32-7; PMID:19857496; http://dx.doi.org/10.1016/j.jim.2009.10.005
29. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res 2005; 22:847-51; PMID:15948027; http://dx.doi.org/10.1007/ s11095-005-4578-z
30. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 2006; 95:1084-96; PMID:16552750; http://dx.doi.org/10.1002/jps.20599
31. Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, Humphries S, et al. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol 1999; 163:6898-906; PMID:10586092
32. Kelly SM, Jess TJ, Price NC. How to study proteins by circular dichroism. Biochim Biophys Acta 2005; 1751:119-39; PMID:16027053; http://dx.doi.org/10. 1016/j.bbapap.2005.06.005
33. Hawe A, Sutter M, Jiskoot W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 2008; 25:1487-99; PMID:18172579; http://dx.doi.org/10.1007/s11095-007-9516-9
34. Demeule B, Lawrence MJ, Drake AF, Gurny R, Arvinte T. Characterization of protein aggregation: the case of a therapeutic immunoglobulin. Biochim Biophys Acta 2007; 1774:146-53; PMID:17142116; http://dx.doi.org/10.1016/j.bbapap.2006. 10.010
35. Pelton JT, McLean LR. Spectroscopic methods for analysis of protein secondary structure. Anal Biochem 2000; 277:167-76; PMID:10625503; http://dx.doi.org/10.1006/abio.1999.4320
36. Imanishi A, Isemura T. Circular dichroic spectra of L-cystine and its dihydrochloride crystals in KBr disc in relation to the circular dichroism of disulfide bonds in proteins. J Biochem 1969; 65:309-12; PMID:5771957
37. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005; 22:1997-2006; PMID:16184451; http://dx.doi.org/10.1007/s11095-005-8177-9
38. Schellekens H. Immunogenicity of therapeutic proteins. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. European Renal Association 2003; 18:1257-9
39. Ottesen JL, Nilsson P, Jami J, Weilguny D, Dührkop M, Bucchini D, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 1994; 37:1178-85; PMID:7895946; http://dx.doi.org/10.1007/BF00399790
40. Weksler ME, Bull G, Schwartz GH, Stenzel KH, Rubin AL. Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin. J Clin Invest 1970; 49:1589-95; PMID:4194090; http://dx.doi.org/10.1172/JCI106376
41. Cerottini JC, Lambert PH, Dixon FJ. Comparison of the immune responsiveness of NZB and NZB X NZW F1 hybrid mice with that of other strains of mice. J Exp Med 1969; 130:1093-105; PMID:4186796; http://dx.doi.org/10.1084/ jem.130.5.1093
42. Biro CE, Garcia G. The Antigenicity of Aggregated and Aggregate-Free Human Gamma-Globulin for Rabbits. Immunology 1965; 8:411-9; PMID:14279046
43. Golub ES, Weigle WO. Studies on the induction of immunologic unresponsiveness. 3. Antigen form and mouse strain variation. J Immunol 1969; 102:389-96; PMID:4179469
44. Fujiwara M, Fujiwara S, Yoshizaki C, Awaya A. Strain differences in the immunogenicity of aggregated human IgG and the adjuvant action of lipopolysaccharide on the low-responder strain of mice. Jpn J Microbiol 1976; 20:141-6; PMID:781351
45. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 1980; 51:691-7; PMID:7419661; http://dx.doi.org/10.1210/jcem-51-4-691
46. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 2011; 28:2393-402; PMID:21544687; http://dx.doi.org/10.1007/s11095-011-0451-4
47. Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS J 2006; 8:E564-71; PMID:17025274; http://dx.doi.org/10.1208/ aapsj080365
48. Stadtman ER. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 1990; 9:315-25; PMID:2283087; http://dx.doi.org/10.1016/0891-5849(90)90006-5
49. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13:114-9; PMID:11154927; http://dx.doi.org/10.1016/S0952- 7915(00)00191-6
50. Li S, Nguyen TH, Schöneich C, Borchardt RT. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry 1995; 34:5762-72; PMID:7727437; http://dx.doi.org/10.1021/ bi00017a008
51. Zimm BH. The dependence of the scattering of light on angle and concentration in linear polymer solutions. J Phys Colloid Chem 1948; 52:260-7; PMID:18918874; http://dx.doi.org/10.1021/j150457a022
52. Aghaie A, Pourfathollah AA, Bathaie SZ, Moazzeni SM, Pour HK, Banazadeh S. Structural study on immunoglobulin G solution after pasteurization with and without stabilizer. Transfus Med 2008; 18:62-70; PMID:18279194; http://dx.doi.org/10.1111/j.1365-3148.2007.00778.x
53. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362:82-8; PMID:20833178; http://dx.doi.org/10. 1016/j.jim.2010.09.005